Ibrutinib for first-line treatment of chronic lymphocytic leukemia in patients aged >= 65 year of age: results with 5 years of follow-up for the RESONATE-2 study Tedeschi, A., Burger, J. A., Barr, P., Robak, T., Owen, C., Ghia, P., Bairey, O., Hillmen, P., Coutre, S., Devereux, S., Grosicki, S., McCarthy, H., Li, J., Simpson, D., Offner, F., Moreno, C., Dai, X., Lal, I., Dean, J., Kipps, T. J. TAYLOR & FRANCIS LTD. 2020: 38–40

View details for Web of Science ID 000534385400028